Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis (Q44245909)

1 December 2017

Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis (English)

1 reference

1 December 2017

0 references

Eriksen EF

1

1 reference

1 December 2017

Melsen F

2

1 reference

1 December 2017

Sod E

3

1 reference

1 December 2017

Barton I

4

1 reference

1 December 2017

Chines A

5

1 reference

1 December 2017

language of work or name

1 reference

1 November 2002

1 reference

1 December 2017

1 reference

1 December 2017

31

1 reference

1 December 2017

5

1 reference

1 December 2017

620-625

1 reference

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Histomorphometric effect of six month treatment with oral Risedronate in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

How many patients are needed? Variation and design considerations in bone histomorphometry

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Bisphosphonate effects and the bone remodeling transient.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Relationship of bone turnover to bone density and fractures

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900869-4

7 January 2021

10.1016/S8756-3282(02)00869-4

Identifiers

DOI

1 reference

1 December 2017

1 reference